Search results for "ERYTHROPOIETIN"

Erythropoietin and iron therapy for preterm infants

1999

Mechanism of action of Rhodiola, salidroside, tyrosol and triandrin in isolated neuroglial cells: An interactive pathway analysis of the downstream e…

2014

Abstract Aim The aim of this study was to identify the targets (genes, interactive signaling pathways, and molecular networks) of Rhodiola rosea extract in isolated neuroglia cells and to predict the effects of Rhodiola extract on cellular functions and diseases. In addition, the potential mechanism of action of Rhodiola rosea extract was elucidated, and the “active principle” among the three isolated constituents (salidroside, triandrin, and tyrosol) was identified. Methods Gene expression profiling was performed using the T98G human neuroglia cell line after treatment with the Rhodiola rosea SHR-5 extract and several of its individual constituents (salidroside, triandrin and tyrosol). An …

Recombinant human erythropoietin (rhEpo) enhances recovery from cisplatin (CDDP) - induced anemia in golden syrian hamsters

1990

The many faces of erythropoietin: from erythropoiesis to a rational neuroprotective strategy

2008

It has been more than 10 years since the discovery that erythropoietin (EPO) and its receptor are expressed by the nervous system. In that brief time, a remarkable acceleration in understanding the...

Poster Presentations

2014

Administration of recombinant human erythropoietin (rHuEpo) improves performance and hence is subject to abuse by athletes. The detection of rHuEpo doping remains a major challenge at present. The aim of the current study was to investigate whether circulating microRNA (miRNA) can be used for detecting r-HuEpo doping. Twenty trained males received rHuEpo injections of 50 IU∙kg -1 body mass every two days for 4 weeks. Blood was obtained 2 weeks before, during and 4 weeks after administration. For this pilot analysis, plasma miRNA expression was assessed at selected time points using the Affymetrix GeneChip 3.0 and the miScript 384 HC PCR Array (Qiagen). For the Affymetrix microarray data, GC…

Reticulocytes in untreated obstructive sleep apnoea.

2008

Background and Aim. The short, repetitive hypoxaemic episodes observed in obstructive sleep apnoea (OSA) may determine small augmentations in mature red blood cells. It is unknown whether they affect reticulocyte release. This study explored whether the number and degree of maturation of circulating reticulocytes may be altered in OSA, possibly through the effect of erythropoietin. Methods. Fifty male adult patients with suspected OSA, normoxic during wakefulness, were studied. After nocturnal polysomnography, a blood sample was withdrawn for blood cells count, erythropoietin, iron and transferrin determination. Reticulocyte concentration and degree of immaturity [high (H), medium (M), or l…

Erythropoietin and Its Double Receptors.

2019

Neuroprotective role of erythropoietin in spinal cord ischemic injury: Where have we been and where are we going?

2018

I read with great interest the study recently published by Yamanaka and colleagues,1 reporting the results of the study aimed to pharmacologically induce b common receptor (bcR) subunit upregulation before ischemia to optimize the neuroprotective effect of erythropoietin (EPO). The authors hypothesized that bcR subunit upregulation by diazoxide (DZ) before ischemia amplifies the neuroprotective effects of EPO in mice after spinal cord injury (SCI). They reported that that optimal bcR upregulation occurred at 36 hours after DZ administration, and the optimal DZ dosage for bcR induction was 20 mg/kg. Motor function at 48 hours after treatment was significantly better preserved in the DZ with …

Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice

2001

Purpose: The effect of recombinant human erythropoietin (Epo) on the radiosensitivity of human tumour xenografts growing in anaemic nude mice was studied. Methods and materials: Anaemia was induced by total body irradiation (TBI) of mice prior to tumour transplantation. The development of anaemia was prevented by Epo (1000 U/kg s.c.) given 3 times weekly starting 2 weeks prior to TBI (5 Gy). Epo treatment did not influence the growth rate of the tumours, which were transplanted into the subcutis of the hind leg of mice. Thirteen days after TBI (tumour volume of approx. 40 mm3), a single-dose irradiation (12 Gy) of the tumour was performed resulting in a growth delay with subsequent regrowth…

Down with the erythropoietin. Long live the erythropoietin!

2009

In recent years the use of erythropoietin has exploded, and the anaemia of patients with chronic renal failure has been practically resolved with the administration of rHuEpo (recombinant human, Erythropoietin). However, as a result of an intense commercial campaign, strong therapies with this growth hormone, prescribed to achieve surprising sporting performances, got athletes to run the risk of thrombosis and vascular accidents because of red blood cells increase. Erythropoietin represents a significant subject of research. In fact, besides the ability of stimulating erythrocyte production, it has many pleiotropic effects. Several studies allow the assertion that EPO, in different concentr…